Background: Pre-antiretroviral therapy (ART) inflammation/ coagulation activation predict clinical outcomes. However, it is unknown whether these processes result in blunted CD4+ count (CD4) responses to ART, thereby resulting in clinical outcomes. The objective of this analysis was to perform exploratory analyses assessing whether pre-ART inflammatory marker levels predicted the CD4 response to ART.
Methods: Analyses were based on data from the SMART and FIRST trials. The SMART study was an international trial evaluating continuous (viral suppression (VS) versus interrupted (drug conversation (DC)) ART and the FIRST trial evaluated 3 first-line ART regimens with ≥2 classes. For this analysis, participants had to be ART-naïve or off ART at randomisation and (re)starting ART and have C-reactive protein (CRP), interleukin-6 (IL-6) and D-dimer measured (available at randomisation for the majority of SMART participants and a selected group from FIRST who participated in previous biomarker studies). Using random effects linear models, we assessed the association between each of the biomarker levels, categorised as quartiles, and change in CD4 from ART-start to 24 months post-ART. Analyses adjusted for pre-ART CD4, study arm, follow-up time and other known confounders. Sensitivity analyses included separate analyses by trials (given it was a selected sub-sample in FIRST) and excluding the DC arm in SMART.
Results: Overall, 1084 individuals (659 from SMART (26% ART naïve) and 425 from FIRST) met the eligibility criteria, providing 8264 CD4 measurements. 75% were male with the mean age of 42 years, 37% and 47% were white and black respectively, and 10% and 33%, respectively, were hepatitis B and C positive. The median (inter-quartile range) baseline CD4 (cells/mm3) were 360 (265-473) overall and 416 (350-530) and 100 (22-300) in SMART and FIRST, respectively. All of the biomarkers were inversely associated with baseline CD4 in FIRST but not in SMART. The figure shows the mean change in CD4 post-ART by quartiles of CRP, IL-6 and D-dimer. In adjusted models, there did not appear to be any clear relationship between changing biomarker levels and mean change in CD4 (P for trend: CRP: 0.97; IL-6: 0.25 and D-dimer: 0.29). Sensitivity analyses yielded similar results.
Conclusions: Pre-ART inflammation/coagulation activation do not predict CD4 response to ART and appear to influence the risk of clinical outcomes through mechanisms other than by blunting long-term CD4 gain.
Figure: Change in CD4 count since (re)initiation of ART by pre-ART quartiles of CRP, IL-6 and D-dimer. Q=quartile (e.g. Q1= 1st quartile etc.).